Feature Lipocine advancing pipeline, PDUFA for oral TRT By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing... May 31, 2016